Myocardial infarction: dual antiplatelets
Indicator
The proportion of patients with acute myocardial infarction who were discharged on dual antiplatelet therapy.
Indicator type
Network / system level indicator.
The indicator would be appropriate to understand and report on the performance of networks or systems of providers.
This document does not represent formal NICE guidance. For a full list of NICE indicators, see our menu of indicators.
To find out how to use indicators and how we develop them, see our NICE indicator process guide.
Rationale
Dual antiplatelet therapy (aspirin plus a second antiplatelet) should be offered to people with acute STEMI or NSTEMI and continued for up to 12 months after an MI (unless contraindicated or they have a separate indication for anticoagulation) to support secondary prevention.
Source guidance
-
Acute coronary syndromes. NICE guideline NG185 (2020), recommendations 1.4.1 and 1.4.13
Specification
Numerator: The number of patients in the denominator discharged on dual antiplatelet therapy.
Denominator: The number of patients discharged from hospital following an admission with acute myocardial infarction.
Calculation: (Numerator/denominator)*100
Exclusions:
-
Patients with contraindication to aspirin or other antiplatelets.
-
Patients treated with anticoagulation.
-
Patients who died in hospital.
Data source: Myocardial Ischaemia National Audit Project (MINAP) dataset.
Minimum population: The indicator would be appropriate to understand and report on the performance of networks or systems of providers.
ISBN: 978-1-4731-5566-4